Opus Genetics, Inc. financial data

Symbol
IRD on Nasdaq
Location
8 Davis Drive, Suite 220, Durham, NC
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 187 % -80.3%
Debt-to-equity 247 % +1995%
Return On Equity -774 % -1116%
Return On Assets -171 % -200%
Operating Margin -445 % -26.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 69M shares +118%
Common Stock, Shares, Outstanding 64.5M shares +146%
Entity Public Float 38.7M USD -56.6%
Common Stock, Value, Issued 6K USD +100%
Weighted Average Number of Shares Outstanding, Basic 70.6M shares +170%
Weighted Average Number of Shares Outstanding, Diluted 70.6M shares +170%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 14.6M USD +74.6%
General and Administrative Expense 24.4M USD +71.8%
Operating Income (Loss) -65.2M USD -121%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -68.2M USD -151%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -68.2M USD -151%
Earnings Per Share, Basic -1 USD/shares -74.1%
Earnings Per Share, Diluted -1 USD/shares -75.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 30.8M USD -15.9%
Accounts Receivable, after Allowance for Credit Loss, Current 2.92M USD +57%
Other Assets, Current 86K USD +68.6%
Assets, Current 35.9M USD -11.1%
Property, Plant and Equipment, Net 212K USD
Assets 36.1M USD -10.6%
Accounts Payable, Current 2.4M USD +184%
Employee-related Liabilities, Current 1.42M USD +247%
Accrued Liabilities, Current 8.15M USD +349%
Liabilities, Current 29.1M USD +378%
Liabilities 30.2M USD +395%
Retained Earnings (Accumulated Deficit) -172M USD -65.7%
Stockholders' Equity Attributable to Parent 5.97M USD -82.6%
Liabilities and Equity 36.1M USD -10.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.99M USD -57.3%
Net Cash Provided by (Used in) Financing Activities 20.5M USD +761%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 64.5M shares +146%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 30.8M USD -15.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 35.4M USD +75.8%
Deferred Tax Assets, Gross 35.4M USD +75.9%
Depreciation 23K USD +360%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -68.2M USD -151%
Property, Plant and Equipment, Gross 25K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 20.3M USD +59.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 9.99M shares -0.14%
Additional Paid in Capital 178M USD +28.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 27K USD
Share-based Payment Arrangement, Expense 3.42M USD +4.33%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%